Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1).
No therapy is known to improve health-related quality of life (HRQoL) or dyspnoea in patients with idiopathic pulmonary fibrosis. The present study investigated longitudinal changes in HRQoL and dyspnoea and explored the effects of bosentan on these end-points during the Bosentan Use in Interstitial Lung Disease (BUILD)-1 trial. In total, 154 subjects received oral bosentan (n = 71) or placebo (n = 83). Changes in HRQoL and dyspnoea from baseline to month (M) 6 and up to M12 were measured using the St George's Respiratory Questionnaire (SGRQ), 36-item short-form health survey (SF-36), Transition Dyspnoea Index and Borg dyspnoea index. Overall, minimal changes occurred in measures of HRQoL and dyspnoea among placebo-treated subjects during the study. The effects of bosentan treatment on HRQoL and dyspnoea in the all-treated population were minimal. However, in the subset of subjects who had undergone surgical lung biopsy for diagnosis of idiopathic pulmonary fibrosis, treatment effects were observed up to M12 in the impact domain of the SGRQ and the physical functioning, general health and role emotional domains of the SF-36. HRQoL and dyspnoea changed minimally during the course of the present study. Observations from exploratory analyses suggested benefits of bosentan on HRQoL among patients who had undergone surgical lung biopsy for diagnosis, and they merit further investigation.
Raghu
G
G
Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA 98195-6522, USA. graghu@u.washington.edu
King
T E
TE
Behr
J
J
Brown
K K
KK
du Bois
R M
RM
Leconte
I
I
Roux
S
S
Swigris
J
J
D000077300:Bosentan; D004417:Dyspnea / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D011658:Pulmonary Fibrosis / Q000150:complications* / Q000188:drug therapy*; D011788:Quality of Life; D013449:Sulfonamides / Q000627:therapeutic use*
D013449:Sulfonamides; D000077300:Bosentan
Ann Med. 2001 Jul;33(5):350-7
11491194
Eur Respir J. 2003 Feb;21(2):267-72
12608440
J Invest Dermatol. 2001 Mar;116(3):417-25
11231316
Med Care. 1992 Jun;30(6):473-83
1593914
Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81
17901413
Intern Med. 2007;46(18):1533-42
17878639
Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):600-8
9279246
Chest. 1984 Jun;85(6):751-8
6723384
J Clin Epidemiol. 2003 Dec;56(12):1170-6
14680667
Respir Med. 2005 Apr;99(4):408-14
15763446
Ann Intern Med. 2001 Jan 16;134(2):136-51
11177318
Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7
15665326
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):646-64
10673212
Med Sci Sports Exerc. 1982;14(5):377-81
7154893
Respir Med. 1991 Sep;85 Suppl B:25-31; discussion 33-7
1759018
N Engl J Med. 2004 Jan 8;350(2):125-33
14711911
Am J Respir Crit Care Med. 1998 Jan;157(1):199-203
9445300